FINAL |
10 OCTOBER 2013 |
Sareum Holdings plc
(“Sareum” or “the Company”)
Final Results
Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, is pleased to announce its final results for the year ended 30 June 2013.
Operational Highlights
Financial Highlights
Post period-end highlights
Tim Mitchell, Chief Executive Officer of the Company, said: “The Company has matured considerably over the period, with real progress made in our key programmes. Our broadened approach of entering into collaborations where appropriate, allowing us to take advantage of the higher asset values associated with licensing later stage programmes, gives us greater flexibility in choosing the right deal for our programmes.”
“With two programmes now in pre-clinical development, we are expecting a busy period in the year ahead.”
Enquiries:
Sareum Holdings plc |
|
Tim Mitchell |
01223 497 700 |
Sanlam Securities UK Limited (Nomad) |
|
Simon Clements |
020 7628 2200 |
Hybridan LLP (Broker) |
|
Claire Noyce / William Lynne |
020 7947 4350 / 4361 |
The Communications Portfolio (Media enquiries) |
|
Ariane Comstive |
+44 (0) 20 7536 2028 |
ariane.comstive@communications-portfolio.co.uk |
|
Annual Results 2013 available as PDF document:Annual Results 2013